# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN-TD
- Date: 1989-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He wants to decide for himself who learns of his HIV diagnosis, and when **S**
- He wants to keep coaching and playing tennis without putting his heart at risk **S**

## Your goals

- HIV-1 viral load not detected by the three-month visit. Target: 1989-04-13. Recorded outcome: Viral load not detected (below 20 copies/mL) at three months, and at six and nine months. **S**
- CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely. Target: 1989-10-19. Recorded outcome: CD4 218 at three months, 262 at six months, and 318 at nine months; trimethoprim-sulfamethoxazole stopped. **S**
- LDL cholesterol below 55 mg/dL by the three-month visit. Target: 1989-04-13. Recorded outcome: LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe. **S**
- Hepatitis B vaccine series completed with a protective antibody level by the three-month visit. Target: 1989-04-13. Recorded outcome: Hepatitis B surface antibody 86 mIU/mL. **S**
- Keep blood pressure below 130/80 mmHg. Target: 1989-07-13. Recorded outcome: Blood pressure 116 to 120 over 72 to 74 at every visit. **S**

## What we agreed to do

- Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three months. Guideline: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020) **S**
- Infectious diseases consultation to co-manage HIV: the regimen and its interactions, opportunistic-infection prophylaxis, the monitoring schedule, and vaccines. Guideline: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition) **S**
- Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on it. Guideline: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition) **S**
- Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerin. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**
- Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visit. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**

## Follow-up

- 1989-01-12: Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations **S**
- 1989-02-09: Four-week check of potassium and creatinine, second hepatitis B vaccine, and infectious diseases consultation **S**
- 1989-04-13: Three-month HIV and lipid review **S**
- 1989-07-13: Six-month HIV and coronary disease review with depression screening **S**
- 1989-08-17: Periodic adult preventive visit **S**
- 1989-10-19: Nine-month HIV review: decision to stop toxoplasmosis maintenance therapy **S**

This teaching document does not replace care from a qualified clinician.
